1. The reason why tonghua dongbao is optimistic about insulin: the income of the third-generation insulin, which will expire soon after listing, will increase. (The gross profit margin of the third generation insulin is higher! The overall gross profit margin of the company will increase rapidly! The incidence of diabetes is increasing year by year. (People exercise less and eat better) The awareness rate of diabetes, the rate of diagnosis and treatment, and the rising rate of control rate brought by graded treatment. (The awareness rate, diagnosis and treatment rate, control rate and foreign body of diabetes in China are very different.) The accelerated growth rate is increasing. The generation of 50-70 years old began to be very popular, which led to an increase in insulin.
In this generation, pensions for people aged 50-70 have become very popular, which leads to an increase in purchasing power. This year, insulin began to return to the clinic, which led to the growth of sales.
3, from the promotion of medical insurance B to A, the generation of 50-70 years old is basically successful in society. The growth rate brought about by the improvement of insulin purchasing power. 10. This generation of children began to change their only children. The only child has a deep affection for his parents and attaches great importance to their health, which leads to an increase in purchasing power.
Extended data;
1, Tianjin CITIC Pharmaceutical Group Co., Ltd. is a large-scale pharmaceutical group with a long history, featuring innovation in traditional Chinese medicine, and listed in Singapore and Shanghai. With more than 40 branches, shareholding and holding companies, the business covers many fields such as Chinese patent medicine, R&D, nutrition and health products manufacturing, and pharmaceutical business.
2. In the third quarter of 2009, CITIC Pharmaceutical achieved its main revenue of 2.06 billion yuan, up 65,438+05.74% year-on-year.
3. In 2009, CITIC Pharmaceutical achieved a net profit of 233 million yuan (basic earnings per share of 0.6 100 yuan), a year-on-year increase of 22.38%. Financial analysis scale growth index
4. In recent three years, the average sales growth rate of ZTE is-1.60%, ranking among all listed companies in its pharmaceutical industry (1411710) and 83/90, with poor extension growth. EPS growth In the past, ZTE's EPS growth rate was -44.30%, ranking between all listed companies in its pharmaceutical industry (1388/ 17 10) and 79/90. The company has poor growth.
5. In recent three years, the average profit growth rate of SINOPEC was -567.60%, ranking first among all listed companies (1574/ 17 10) and pharmaceutical industry (86/90). Poor profitability. EPS stability
6. In the past, ZTE's EPS stability ranked 84/90 among all listed companies in its pharmaceutical industry (1567/ 17 10). The company's business stability is poor.